Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Improving outcomes in KRAS-mutant pancreatic cancer

John Strickler • 6 Jun 2022
ASCO 2022
Gastrointestinal Cancer Pancreatic Cancer Sotorasib

John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the use of sotorasib and KRAS inhibitors in pancreatic cancer, as well as potential combinations to improve outcomes in KRAS-mutant patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from John Strickler

1:25
Real-world treatment patterns for HER2-amplified colorectal cancer
John Strickler • 21 Oct 2023
0:44
Using ctDNA to identify mutations in colorectal cancer
John Strickler • 21 Oct 2023
0:58
MOUNTAINEER: clinical relevance of genomic profiling for tucatinib + trastuzumab treatment in mCRC
John Strickler • 21 Oct 2023
2:28
MOUNTAINEER: impact of genomic alterations on tucatinib plus trastuzumab activity in mCRC
John Strickler • 21 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals